Taysha Gene Therapies Grants Employee Stock
Analysis based on 6 articles · First reported Apr 03, 2026 · Last updated Apr 03, 2026
The market impact is minor, as Taysha Gene Therapies's stock grant to new employees is a routine corporate action. It may be viewed as a slight positive for Taysha Gene Therapies as it indicates talent acquisition.
Taysha Gene Therapies announced that its Compensation Committee granted restricted stock units (RSUs) representing 300,000 shares and an option to purchase 92,400 shares of its common stock to four new employees on April 1, 2026. These grants were made under the Taysha Gene Therapies, Inc. 2023 Inducement Plan, in accordance with Nasdaq-100 Listing Rule 5635(c)(4), as an inducement for their employment. The RSUs and stock options will vest over four years, subject to continued service.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard